Medical Oncologist
HER2-targeted treatment
HER2-Positive Breast Cancer: — The Full Targeted Therapy Roadmap
HER2-positive breast cancer overproduces the HER2 protein, which signals cancer cells to grow. A class of drugs called anti-HER2 targeted therapies is designed to block that signal — and they are now central to treatment at every stage of the disease.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Driven by a specific protein — HER2-positive tumours have too many copies of the HER2 gene, causing the protein to flood the cell surface and drive rapid growth.
- Three drug classes work differently — Monoclonal antibodies, antibody-drug conjugates, and tyrosine kinase inhibitors each block HER2 by a different mechanism and are used at different points in treatment.
- Given alongside or after chemotherapy — Anti-HER2 therapy is almost always combined with chemotherapy rather than used alone, especially in early-stage disease.
- Treatment continues after surgery — For most people with early-stage HER2-positive breast cancer, targeted therapy continues for a defined period after surgery, per NCCN and ASCO guidelines.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
HER2-positive breast cancer overproduces the HER2 protein, driving tumour growth. A class of drugs called anti-HER2 targeted therapies is designed to block that signal directly. NCCN and ASCO recommend anti-HER2 therapy as standard of care at every stage, usually given alongside or after chemotherapy.
What does the HER2-positive breast cancer treatment roadmap look like?
HER2 testing confirmed
Your biopsy tissue is tested using IHC and, if needed, FISH to confirm HER2-positive status. Treatment does not begin until this result is in hand.
Staging and treatment planning
Your oncologist establishes the stage — localised, locally advanced, or metastatic — and presents your case at a multidisciplinary team meeting. Stage determines whether targeted therapy starts before surgery, after, or without surgery.
Targeted therapy begins
Anti-HER2 treatment starts, almost always combined with chemotherapy. Monoclonal antibodies are given as day-care infusions. Some tyrosine kinase inhibitors are oral tablets taken at home.
Response is assessed
After several cycles, scans assess how the tumour is responding. In early-stage disease, the response seen at surgery is a key milestone that directly guides which drug comes next.
Surgery (early-stage disease)
Most people with early HER2-positive disease have surgery after neoadjuvant treatment. The pathology report shows whether residual cancer remains, which determines the next drug choice.
Ongoing targeted therapy
Anti-HER2 treatment continues after surgery for a defined period, per NCCN and ASCO guidelines. In metastatic disease, targeted therapy continues as long as the cancer is responding and side effects are manageable.
How do HER2-targeted drugs actually work?
Anti-HER2 drugs work by targeting a protein receptor that floods the surface of HER2-positive cancer cells and sends a constant growth signal inward. The drugs exploit that overabundance — blocking the receptor from outside, preventing the signal from firing inside the cell, or using the receptor as a delivery address to carry chemotherapy directly into cancer cells.
No single drug covers all three mechanisms. Most regimens combine agents from more than one class, using each at the stage where the evidence supports it best.
The drug class your oncologist recommends depends on the stage of your disease, whether residual cancer was found at surgery, whether the cancer has spread to the brain, and which treatments you have already had.
Which drugs are used, and what does each one do?
- Trastuzumab (monoclonal antibody)
- The foundational anti-HER2 drug in use since the late 1990s. It binds to the HER2 receptor on the cell surface and blocks the growth signal. It is the backbone of most HER2-positive regimens and is given as an intravenous infusion.
- Pertuzumab (monoclonal antibody)
- A second antibody that binds to a different part of the HER2 protein, preventing two receptors from pairing — a separate blocking mechanism from trastuzumab. NCCN guidelines recommend it alongside trastuzumab in certain early-stage and metastatic settings.
- Trastuzumab emtansine — T-DM1 (antibody-drug conjugate)
- Uses trastuzumab as a delivery vehicle to carry a chemotherapy payload directly into HER2-positive cells. ASCO and NCCN guidelines recommend it when residual cancer remains after neoadjuvant treatment. It delivers its payload with more precision than conventional chemotherapy.
- Trastuzumab deruxtecan — T-DXd (antibody-drug conjugate)
- A newer antibody-drug conjugate recommended by NCCN for metastatic or previously treated HER2-positive disease. It carries a different payload from T-DM1 and also has activity in HER2-low disease, a category now recognised in ASCO and ESMO guidance.
- Lapatinib (tyrosine kinase inhibitor — oral)
- An oral tablet that blocks the HER2 and EGFR signals from inside the cell, at the point where they are produced rather than at the surface. Used in certain metastatic settings and for brain metastases, as it can cross the blood-brain barrier in a proportion of patients.
- Tucatinib and neratinib (tyrosine kinase inhibitors — oral)
- Newer oral TKIs. Tucatinib is a HER2-selective inhibitor recommended by NCCN in combination with trastuzumab and capecitabine for certain metastatic settings, including brain metastases. Neratinib is used in extended adjuvant treatment after early-stage HER2-positive disease.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What should you expect during HER2-targeted treatment?
Anti-HER2 monoclonal antibodies are given as intravenous infusions, typically every three weeks. The first infusion takes the longest; subsequent ones are shorter. Most people receive them as day care and return home the same day.
Cardiac monitoring is part of standard treatment. HER2-targeted antibodies can, in a proportion of patients, reduce the heart's pumping function. Your team will check this with echocardiograms before treatment begins and at regular intervals during it.
The side effects you notice most are often from the chemotherapy given alongside, not the anti-HER2 drug itself. Fatigue, hair changes, and nausea are chemotherapy effects. The targeted drug's own side effects — infusion reactions, joint aches, diarrhoea with some oral agents — are generally distinct and usually manageable.
Did you know?
Before anti-HER2 targeted therapy existed, HER2-positive breast cancer carried a significantly worse outlook than other subtypes. The introduction of trastuzumab-based treatment changed that course — and it remains one of the clearest examples in oncology of a targeted drug altering the natural history of a disease.
NCCN, ASCO, and ESMO now list HER2-positive breast cancer as a distinct, testable subtype with its own treatment pathway — which is why confirming HER2 status before any treatment decision is non-negotiable.
Source: NCCN Guidelines for Breast Cancer; ASCO Clinical Practice Guidelines
Questions families ask about HER2-positive treatment
How reliable is the HER2 test, and what if there is a borderline result?
HER2 testing follows a two-step process set by ASCO and CAP guidelines: immunohistochemistry (IHC) first, and if the result is ambiguous, fluorescence in situ hybridisation (FISH) to count actual gene copies in the tumour. An IHC 2+ result that FISH confirms as amplified is treated as HER2-positive; an IHC 2+ result with a FISH-negative finding is not. If you are uncertain about your result, ask your oncologist to show you both the IHC score and the FISH ratio together. A second opinion on the pathology slide is reasonable and sometimes formally recommended.
Can HER2 status change after treatment or if the cancer comes back?
Yes, and this matters for treatment decisions. HER2 status can shift between the primary tumour and a metastatic site, or between original diagnosis and recurrence. This is why ASCO and ESMO recommend re-testing tumour tissue when the disease recurs rather than relying solely on the original result. A tumour that was HER2-negative at first diagnosis can test HER2-positive later, and the reverse has also been documented. Ask your oncologist whether re-testing the new biopsy site is planned if the cancer grows or spreads.
How long does HER2-targeted therapy continue?
In early-stage disease, NCCN and ASCO guidelines set a standard duration of anti-HER2 therapy after surgery, and an extended adjuvant phase with a different agent may be recommended in certain higher-risk cases. In metastatic disease there is no fixed endpoint — treatment continues as long as the cancer is responding and side effects are acceptable. Ask your oncologist at the start of treatment what the planned duration is for your specific regimen, and what the key decision points are along the way.
What if residual cancer is found at surgery?
Finding residual cancer in the breast or lymph nodes after neoadjuvant treatment is important clinical information, not a failure. NCCN and ASCO guidelines recommend switching to trastuzumab emtansine (T-DM1) rather than continuing the original regimen, because the evidence shows this reduces the risk of recurrence in that situation. Your oncologist should explain the pathology result clearly, what it means for the next treatment step, and what the switch is expected to achieve. You are entitled to ask for that explanation in plain language.
Is HER2-targeted therapy available at CION?
Anti-HER2 infusion regimens are given as day care at CION centres, and response-assessment scans including PET-CT are coordinated with partner imaging centres. CION does not provide CAR-T or cell therapy — anti-HER2 monoclonal antibodies and antibody-drug conjugates are not cell therapies and are routinely administered. Oral tyrosine kinase inhibitors are self-administered tablets your oncologist prescribes; CION coordinates the cardiac monitoring and other interval tests required throughout your treatment.
What does HER2-low mean, and does it change my treatment?
HER2-low is a category recognised in 2022 ASCO guidance for tumours that express some HER2 protein but fall below the threshold for HER2-positive. Previously these tumours were grouped as HER2-negative and received no anti-HER2 treatment. Trastuzumab deruxtecan (T-DXd) has demonstrated activity in HER2-low metastatic breast cancer and is now recommended by NCCN in that setting. If your pathology report reads IHC 1+ or IHC 2+ with a negative FISH result, ask your oncologist whether the HER2-low question is relevant to your current or future treatment plan.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What does HER2-positive mean in breast cancer?
HER2-positive means the tumour has extra copies of the HER2 gene, causing the HER2 protein to be overproduced on the cell surface and driving a continuous growth signal. It is confirmed by IHC and FISH testing on biopsy tissue. The reason it matters is that a specific class of drugs — anti-HER2 targeted therapies — can block that signal directly, and NCCN and ASCO list those drugs as standard of care at every stage.
Can HER2-positive breast cancer be treated without chemotherapy?
For most people, anti-HER2 therapy is given alongside chemotherapy rather than instead of it, particularly in early-stage disease. NCCN guidelines include chemotherapy as part of nearly all curative-intent HER2-positive regimens. There are individual situations — very small tumours, significant comorbidities, or other clinical factors — where your oncologist may discuss a different approach, but that is an individual decision that needs to be explained with reference to your specific stage and tumour characteristics.
Is trastuzumab the same as immunotherapy?
No. Trastuzumab is a monoclonal antibody that targets the HER2 protein directly on cancer cells. Immunotherapy — specifically checkpoint inhibitors — works by releasing brakes on the immune system so it can recognise cancer more broadly. They work by completely different mechanisms. Trastuzumab has been used for HER2-positive breast cancer since the late 1990s and has a well-characterised side effect profile. Checkpoint immunotherapy is not a standard part of most HER2-positive breast cancer regimens.
What cardiac monitoring is needed during HER2-targeted treatment?
Your heart's pumping function — called the ejection fraction — is checked before treatment begins and at regular intervals during it, because anti-HER2 antibodies can reduce it in a proportion of patients. This is done by echocardiogram. Most reductions are reversible when treatment is paused or stopped, and many people complete their full course without any cardiac change. Tell your team promptly if you develop shortness of breath, unusual leg swelling, or unexpected fatigue during treatment.
What is the difference between neoadjuvant and adjuvant targeted therapy?
Neoadjuvant therapy is given before surgery to shrink the tumour and assess how the cancer responds. Adjuvant therapy is given after surgery to reduce the risk of recurrence. In early HER2-positive breast cancer, NCCN and ASCO typically recommend neoadjuvant chemotherapy plus anti-HER2 therapy, followed by surgery, then adjuvant anti-HER2 therapy. What the surgeon finds at the time of the operation — specifically whether any residual cancer is present — directly determines which drug is used in the adjuvant phase.
What happens if HER2-targeted therapy stops working?
If the cancer progresses on one anti-HER2 regimen, NCCN and ASCO guidelines recommend switching to a different drug class rather than stopping targeted therapy altogether. Newer antibody-drug conjugates and oral tyrosine kinase inhibitors provide additional lines of treatment. Your oncologist will likely recommend re-testing to confirm HER2 status on current disease before presenting next-line options. Progression on a first-line treatment does not exhaust the anti-HER2 pathway.